【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 13
1.1 List of Tables 20
1.2 List of Figures 24
2 Introduction 27
2.1 Catalyst 27
2.2 Related Reports 28
2.3 Upcoming Related Reports 28
3 Disease Overview 29
3.1 Etiology and Pathophysiology 31
3.1.1 Diabetic Nephropathy 31
3.1.2 Diabetic Retinopathy 33
3.1.3 Diabetic Neuropathy 34
3.2 Prognosis 35
3.3 Quality of Life 36
3.4 Symptoms 37
4 Epidemiology 38
4.1 Diabetic Nephropathy 38
4.1.1 Disease Background 38
4.1.2 Risk Factors and Comorbidities 39
4.1.3 Global Trends 40
4.1.4 Forecast Methodology 43
4.1.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Diabetes 47
4.1.6 Forecast Assumptions and Methods — Diabetic Nephropathy 51
4.1.7 Epidemiology Forecast for Diabetic Nephropathy (2012-2022) 53
4.1.8 Discussion 59
4.2 Diabetic Retinopathy 61
4.2.1 Disease Background 61
4.2.2 Risk Factors and Comorbidities 63
4.2.3 Global Trends 63
4.2.4 Forecast Methodology 68
4.2.5 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 74
4.2.6 Forecast Assumptions and Methods — Diabetic Retinopathy 78
4.2.7 Epidemiology Forecast for Diabetic Retinopathy (2012-2022) 80
4.2.8 Discussion 87
4.3 Diabetic Neuropathy 89
4.3.1 Disease Background 89
4.3.2 Risk Factors and Comorbidities 90
4.3.3 Global Trends 90
4.3.4 Forecast Methodology 93
4.3.5 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 98
4.3.6 Forecast Assumptions and Methods — Diabetic Neuropathy 102
4.3.7 Epidemiology Forecast for Diabetic Neuropathy (2012-2022) 103
4.3.8 Discussion 111
4.3.9 Limitations of the Analysis 112
4.3.10 Strengths of the Analysis 113
5 Disease Management 114
5.1 Treatment Overview 114
5.1.1 Diagnosis and Referrals 114
5.1.2 Screening 116
5.1.3 Treatment Guidelines 117
5.2 US 124
5.2.1 Diagnosis 124
5.2.2 Clinical Practice 126
5.3 France 128
5.3.1 Diagnosis 128
5.3.2 Clinical Practice 129
5.4 Germany 131
5.4.1 Diagnosis 131
5.4.2 Clinical Practice 132
5.5 Italy 133
5.5.1 Diagnosis 133
5.5.2 Clinical Practice 134
5.6 Spain 136
5.6.1 Diagnosis 136
5.6.2 Clinical Practice 137
5.7 UK 138
5.7.1 Diagnosis 138
5.7.2 Clinical Practice 141
5.8 Japan 144
5.8.1 Diagnosis 144
5.8.2 Clinical Practice 146
6 Competitive Assessment 148
6.1 Overview 148
6.2 Strategic Competitor Assessment 149
6.3 Diabetic Nephropathy: Product Profiles – Major Classes and Brands 153
6.3.1 Angiotensin-Converting Enzyme (ACE) Inhibitors 153
6.3.2 Angiotensin Receptor Blockers 157
6.4 Diabetic Retinopathy: Product Profiles – Major Classes and Brands 161
6.4.1 Lucentis (ranibizumab) 161
6.4.2 Avastin (bevacizumab) 167
6.4.3 Corticosteroid Intravitreal Implants 172
6.5 Diabetic Neuropathy: Product Profiles – Major Classes and Brands 177
6.5.1 Tricyclic Antidepressants 177
6.5.2 Serotonin-Norepinephrine Reuptake Inhibitors – Cymbalta (duloxetine) and Effexor (venlafaxine) 180
6.5.3 Anticonvulsants – Neurontin (gabapentin) and Lyrica (pregabalin) 185
6.5.4 Opioids 191
6.5.5 Epalrestat 194
7 Opportunity and Unmet Need 198
7.1 Overview 198
7.2 Unmet Needs 199
7.2.1 Unified Treatment for the Microvascular Complications of Diabetes 199
7.2.2 Optimization of Personalized Therapy in the Microvascular Complications of Diabetes 199
7.2.3 Treatment for Diabetic Nephropathy that Would Prevent ESRD 201
7.2.4 Cardio- and Renoprotective Therapy for Diabetic Nephropathy 202
7.2.5 Efficient Therapy for Retinopathy 203
7.2.6 Convenient Administration in Diabetic Retinopathy Treatment 203
7.2.7 Treatment for Diabetic Neuropathy 204
7.3 Unmet Needs Gap Analysis 205
7.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 207
7.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 207
7.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 208
7.7 Opportunity: Topical Treatment for Diabetic Retinopathy 208
7.8 Opportunity: Treatment for Diabetic Neuropathy 209
8 Pipeline Assessment 210
8.1 Overview 210
8.2 Clinical Trial Mapping 212
8.2.1 Clinical Trials by Country 212
8.3 Clinical Trials by Phase and Trial Status 213
8.4 Promising Drugs in Clinical Development 215
8.4.1 Eylea (aflibercept) 217
8.4.2 Optina (danazol) 223
8.4.3 Atrasentan Hydrochloride 229
8.4.4 Ranirestat 234
9 Current and Future Players 239
9.1 Overview 239
9.2 Trends in Corporate Strategy 241
9.3 Company Profiles 244
9.3.1 Roche 244
9.3.2 Novartis 246
9.3.3 Regeneron 248
9.3.4 Bayer 250
9.3.5 Eli Lilly 251
9.3.6 Pfizer 254
9.3.7 AbbVie 256
10 Market Outlook 259
10.1 Global Markets 259
10.1.1 Forecast 259
10.1.2 Drivers and Barriers – Global Issues 263
10.2 US 266
10.2.1 Forecast 266
10.2.2 Key Events 271
10.2.3 Drivers and Barriers 271
10.3 France 274
10.3.1 Forecast 274
10.3.2 Key Events 279
10.3.3 Drivers and Barriers 279
10.4 Germany 282
10.4.1 Forecast 282
10.4.2 Key Events 287
10.4.3 Drivers and Barriers 287
10.5 Italy 290
10.5.1 Forecast 290
10.5.2 Key Events 295
10.5.3 Drivers and Barriers 295
10.6 Spain 298
10.6.1 Forecast 298
10.6.2 Key Events 303
10.6.3 Drivers and Barriers 303
10.7 UK 306
10.7.1 Forecast 306
10.7.2 Key Events 311
10.7.3 Drivers and Barriers 311
10.8 Japan 314
10.8.1 Forecast 314
10.8.2 Key Events 320
10.8.3 Drivers and Barriers 320
11 Appendix 323
11.1 Bibliography 323
11.2 Abbreviations 347
11.3 Methodology 354
11.4 Forecasting Methodology 354
11.4.1 Diagnosed Patients 354
11.4.2 Percent Drug-Treated Patients 355
11.4.3 Drugs Included in Each Therapeutic Class 355
11.4.4 Launch and Patent Expiry Dates 355
11.4.5 General Pricing Assumptions 356
11.4.6 Individual Drug Assumptions 357
11.4.7 Generic Erosion 361
11.4.8 Pricing of Pipeline Agents 361
11.5 Physicians and Specialists Included in this Study 362
11.6 About the Authors 364
11.6.1 Analyst II – CVMD 364
11.6.2 Therapy Director – CVMD and Infectious Disease 364
11.6.3 Senior Epidemiologist 365
11.6.4 Global Head of Healthcare 365
11.7 About GlobalData 366
11.8 Disclaimer 366
【レポート販売概要】
■ タイトル:糖尿病の微小血管合併症:グローバル医薬品市場予測・分析(~2022)■ 英文:PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022
■ 発行日:2013年12月31日
■ 調査会社:GlobalData
■ 商品コード:GDHC62PIDR
■ 調査対象地域:グローバル
- 世界の遺伝子治療市場予測(~2020)Gene therapy is one of the most widely researched fields in the healthcare industry. The high potential of gene therapy to cure various chronic diseases makes it a popular research area. Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others. According to RNCOS’ new r …
- 地理情報システム(GIS)ソフトウェアの世界市場:コンポーネント別(ソフトウェア、サービス)、GISソフトウェア種類別(デスクトップGIS、サーバーGIS、開発者GIS、モバイルGIS、その他)、機能別(マッピング、測量、位置情報サービス、ナビゲーション・テレマティクス、およびその他)、組織規模別(中小企業、大企業)、業種別(防衛、農業、石油・ガス、建設、公益事業、輸送・物流、その他)A geographic information system (GIS) is a system developed to capture, store, manipulate, analyze, manage, and present all types of geographical data. GIS software contains additional tools compared to a relational database. It provides tools and functions to input and store spatial data or geographic data. It facilitates users to perform geographic query, run analysis model and display geographi …
- 分子量マーカーの世界市場:DNAマーカー、プロテイン・マーカー、RNAマーカーThe global molecular weight markers market comprises of DNA, Protein and RNA markers. The molecular weight markers market is further divided on the basis of type and size. The molecular weight markers by type consist of 3 segments, namely, prestained, unstained and specialty markers. DNA molecular weight markers by size consist of 5 subsegments: below 50 base pair (bp), 50 bp to 100 bp, 100 bp to …
- ノルウェーの水力発電市場2016:発電能力、生産、投資動向、制度、企業Hydropower in Norway, Market Outlook to 2030, Update 2016 - Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles Summary "Hydropower in Norway, Market Outlook to 2030, Update 2016 - Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles” is the latest report from GlobalData, the industry analy …
- 世界のティッシュペーパー市場動向(2012-2016)TechNavio's analysts forecast the Global Tissue Paper market to grow at a CAGR of 4.9 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand of tissue paper for personal hygiene. The Global Tissue Paper market has also been witnessing an increase in the number of international trips between the western and eastern worlds. However, the …
- 商業ビルオートメーションシステムの世界市場展望2017-20276According to Stratistics MRC, the Global Commercial Building Automation Systems Market is accounted for $82.60 billion in 2017 and is expected to reach $144.36 billion by 2026 growing at a CAGR of 6.4% during the forecast period. Growth in need for energy-efficient commercial buildings is one of the major factors driving the market growth. However, lack of skilled labors and high cost of implement …
- 世界のFTTx装置メーカー動向:戦略、技術、市場シェアn/a
- グローバル製薬業界における事業提携、ライセンシング、投資及びM&A動向:Q4 2013Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013 Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides …
- 世界の化粧板市場2015The Global Decorative Laminates Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Decorative Laminates industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Decorative Laminates market analysis is provided for the international markets including develop …
- 自動車用排ガス熱回収(EGHR)システムの世界市場2018-2022About automotive exhaust gas heat recovery system (EGHR) An automotive exhaust gas heat recovery system (EGHR) is located in the exhaust system of the vehicle. This compact unit recovers heat from the vehicle exhaust and utilizes the heat to warm the engine fuels and the cabin. Technavio’s analysts forecast the Global automotive exhaust gas heat recovery system (EGHR) market to grow at a CAGR of 4 …
- 有機食品/有機飲料の世界市場2015-2019About Organic Food and Beverages Organic food and beverages are products produced using organic farming. As the name suggests, organic farming uses only natural and biological processes and raw materials. Organic farming involves the use of organic enhancers that are not harmful. Organic food and beverages do not use unnatural techniques such as irradiation during processing, or contain synthetic …
- 血液バンク用機器の世界市場2015This report reviews current instrumentation technologies, and compares features of over 20 leading blood banking automated and semiautomated analyzers.Contains 25 pages
- 世界のベトロニクス(軍用車両用電子機器)市場(2014 – 2020)The global vehicle electronics (Vetronics) market research report provides an in-depth analysis of the Vetronics market on the basis of application, sub-systems, military land vehicles, and geographies. This report provides information about the current trends existing in the market along with the upcoming trends. It throws light on the drivers, restraints, challenges, and opportunities, which imp …
- 世界のパパニコロウ塗抹/HPV検査市場The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technologi …
- 生体吸収性スキャフォールドの世界市場分析および予測MediPoint: Bioabsorbable Scaffolds - Global Analysis and Market Forecasts Summary Coronary artery disease (CAD) and peripheral artery disease (PAD) are global public health and socioeconomic issues that affect millions of lives each year. Bioabsorbable scaffolds (BAS), which provide transient support to the vessel, are viable alternatives to permanent drug-eluting stents (DES) and bare metal stent …